Insulin and glucagon work as opposing signals that keep blood sugar within a narrow range, roughly 70 to 100 mg/dL when you haven’t eaten recently. Both hormones are made by clusters of cells in the pancreas, and they respond to the same trigger, blood glucose, in opposite directions: rising glucose stimulates insulin release and suppresses glucagon, while falling glucose does the reverse. The result is a continuous tug-of-war that prevents blood sugar from drifting dangerously high or crashing dangerously low. That simple seesaw, though, turns out to involve several additional hormones, signals from the gut and brain, and a surprisingly intricate conversation among the cells that sit side by side inside the pancreas.
What Happens Inside the Pancreas When Blood Sugar Rises
The pancreas contains tiny clusters of hormone-producing cells called islets. Each islet holds three main cell types: beta cells that make insulin, alpha cells that make glucagon, and delta cells that make somatostatin (more on those shortly). When you eat and glucose enters the bloodstream, beta cells are the first to respond. Glucose flows into the beta cell, gets broken down through normal metabolism, and produces ATP, the cell’s energy currency. As the ratio of ATP to ADP climbs, it forces a specific type of potassium channel shut. With those channels closed, the electrical charge across the cell membrane shifts, calcium rushes in, and that calcium influx triggers the release of insulin-filled packets into the blood.1PubMed Central. Glucose sensing in the pancreatic beta cell: a computational systems analysis The whole sequence, from glucose entry to insulin secretion, takes just a few minutes.
The same type of potassium channel exists in alpha cells, but its role there is different and still debated. Research using mice with a key glucose-sensing enzyme knocked out specifically in alpha cells showed that those cells also use a rising ATP/ADP ratio and potassium channel closure as part of how they detect glucose.2Nature Communications. α-cell glucokinase suppresses glucose-regulated glucagon secretion When glucose is high, alpha cells reduce glucagon output. When glucose drops, that brake comes off and glucagon pours out. The net effect after a meal is a sharp rise in circulating insulin with a simultaneous dip in glucagon.
How the Two Hormones Act on the Liver
The liver is the main stage where insulin and glucagon exert their opposing effects. Think of the liver as a glucose warehouse. After a meal, insulin tells the liver to absorb glucose from the blood and store it as glycogen, a compact storage form. Insulin also promotes fat synthesis in the liver and generally puts the organ in “storage mode.”3PubMed Central. Resolving the Paradox of Hepatic Insulin Resistance Glucagon does the opposite: it tells the liver to break down glycogen and release glucose back into the bloodstream. When glycogen stores run low during a prolonged fast, glucagon also stimulates the liver to manufacture brand-new glucose from amino acids and other precursors.4Physiological Reviews. Hepatic glucagon action: beyond glucose mobilization
The ratio between the two hormones matters as much as either one alone. When insulin dominates (after eating), the liver stores fuel. When glucagon dominates (during fasting or exercise), the liver releases fuel. Blood sugar stays stable not because one hormone hits a fixed set point, but because the balance between them shifts smoothly as conditions change.
The Third Player Most People Don’t Hear About
Delta cells, the smallest population inside each islet, release somatostatin, a hormone that puts the brakes on both insulin and glucagon secretion. Somatostatin acts locally, right there inside the islet, as a kind of volume knob. When glucose is high and both beta and alpha cells are active, signals from those neighboring cells amplify somatostatin release from delta cells. Somatostatin then feeds back to dampen secretion from all three cell types, including delta cells themselves.5PubMed Central. The somatostatin-secreting pancreatic δ-cell in health and disease
Why does this matter? Without somatostatin acting as a moderator, insulin and glucagon secretion could overshoot. Modeling studies that combine all three cell types show that the inhibitory effects of glucose on glucagon secretion cannot be fully explained by alpha-cell biology alone. You need the paracrine crosstalk, where neighboring cells communicate through locally released signals, to reproduce what researchers actually observe in living islets.6PubMed Central. Paracrine regulation of glucagon secretion: the β/α/δ model In other words, the feedback loop is not a clean two-hormone seesaw; it is a three-way conversation happening in a space smaller than a grain of sand.
What Changes During Fasting
When you skip a meal or sleep through the night, blood sugar gradually drifts downward. Beta cells sense the decline and throttle back insulin secretion. At the same time, alpha cells ramp up glucagon output. Glucagon’s primary job in a fasted state is to maintain the liver’s glucose production so the brain and red blood cells, which depend heavily on glucose, keep getting a steady supply.7Journal of Diabetes Science and Technology. The Physiology of Glucagon
During shorter fasts of 12 to 16 hours, the liver mostly breaks down stored glycogen. As fasting extends beyond a day, glycogen reserves thin out and the liver shifts toward making new glucose from scratch, a process driven largely by glucagon. Insulin doesn’t vanish entirely; a low baseline level persists and prevents the liver from overproducing glucose. The balance between these two hormones at any given moment determines how much glucose enters the bloodstream.
How Exercise Shifts the Balance
Physical activity creates an interesting metabolic challenge: your muscles are burning glucose at a faster rate, yet blood sugar needs to stay in range. The body solves this by tweaking the insulin-to-glucagon ratio. During light to moderate exercise, insulin levels drop and glucagon levels rise, nudging the liver to release more glucose and match what muscles are consuming. Classic research showed that if these hormonal shifts don’t happen, for instance if someone has too much circulating insulin, blood sugar can fall low enough to cause exhaustion.8PubMed Central. Role of changes in insulin and glucagon in glucose homeostasis in exercise
This is something people with type 1 diabetes deal with directly. If they inject insulin before a workout and the dose is too high relative to what they need, the normal glucagon response can’t fully compensate, and hypoglycemia becomes a real risk. Understanding that exercise naturally suppresses insulin and boosts glucagon in a healthy body helps explain why managing blood sugar around physical activity is one of the trickiest parts of living with diabetes.
The Emergency Backup System for Low Blood Sugar
When blood sugar drops sharply, the body doesn’t rely on a single fix. Glucagon is the first responder: alpha cells detect the falling glucose and release a burst of glucagon to drive liver glucose output upward. But if glucagon alone isn’t enough, epinephrine (adrenaline) kicks in as a backup, stimulating the liver through a different pathway. Research in the 1980s established that the body uses redundant counterregulatory systems: glucagon is the primary defense, and epinephrine largely compensates when glucagon is deficient. Dangerous hypoglycemia tends to occur only when both systems fail simultaneously.9American Journal of Physiology-Endocrinology and Metabolism. Roles of glucagon and epinephrine in hypoglycemic and nonhypoglycemic glucose counterregulation in humans
This layered design helps explain why most people never experience severe hypoglycemia even after a long fast or heavy exercise. But it also highlights the vulnerability of people with type 1 diabetes, whose alpha cells gradually lose the ability to mount a normal glucagon response to low blood sugar. In those individuals, defective epinephrine responses on top of blunted glucagon can lead to dangerous episodes of “hypoglycemia unawareness,” where blood sugar plummets without warning symptoms.10PubMed Central. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus
How the Loop Breaks Down in Diabetes
In type 1 diabetes, the immune system destroys beta cells. Without beta cells, there is no insulin production and very little of the local signaling that normally keeps alpha cells in check. One leading explanation for why glucagon responses become abnormal in type 1 diabetes points to the loss of those tiny, within-the-islet changes in insulin concentration that alpha cells rely on as a cue.11Diabetes Care. Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes With the beta cells gone, alpha cells lose a critical piece of their feedback signal. Glucagon secretion becomes erratic: too much when blood sugar is already high, and not enough when blood sugar falls dangerously low.
Type 2 diabetes involves a different breakdown. Here, the body’s tissues become resistant to insulin, so the pancreas compensates by pumping out more of it. But glucagon doesn’t stay quiet either. People with screen-detected type 2 diabetes showed roughly 30% higher fasting glucagon levels compared to people with normal glucose tolerance. They also had a delayed suppression of glucagon after eating, meaning the liver kept producing glucose even when it shouldn’t have been.12PubMed. Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation So in type 2 diabetes, the seesaw doesn’t just tip toward too little insulin; it tips toward too much glucagon at the same time, compounding the problem.
Signals From the Gut That Fine-Tune the Loop
The insulin-glucagon balance isn’t set by blood glucose alone. When food hits the gut, specialized cells in the intestinal lining release hormones called incretins. The two major ones are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both amplify insulin secretion when glucose is present, but they do so in different ways. GIP appears to be more potent at boosting insulin release directly, while GLP-1’s main effect is suppressing glucagon secretion and slowing the rate at which the stomach empties food into the intestine.13PubMed. The incretin system in healthy humans: The role of GIP and GLP-1
This distinction has practical medical significance. GLP-1 receptor agonists, the drug class that includes semaglutide (Ozempic, Wegovy) and liraglutide, exploit the glucagon-suppressing and stomach-slowing effects of GLP-1 to lower blood sugar and reduce appetite. The success of these medications is, in a real sense, a direct application of incretin biology: they tilt the insulin-glucagon ratio toward insulin dominance after meals while also reducing how quickly nutrients hit the bloodstream.14PubMed. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
The Brain’s Overlooked Role
Isolated islets in a lab dish can sense glucose and secrete hormones just fine on their own, which is why most descriptions of the feedback loop focus exclusively on what happens in the pancreas and liver. But the pancreas is richly innervated, and research on brain-pancreas connections shows that experimentally manipulating the nerve supply to the pancreas alters both insulin and glucagon release in living animals. The hypothalamus, in particular, monitors blood glucose and can send neural signals that adjust islet hormone output as part of a broader homeostatic system. The brain doesn’t override the local islet response so much as layer another level of regulation on top of it, coordinating blood sugar control with other priorities like appetite, body temperature, and stress responses.
Why Glucagon Got Less Attention Than Insulin
Insulin was isolated in 1921, and its ability to rescue people with diabetes made it one of the most celebrated discoveries in medicine. Glucagon was actually noticed just a year or two later, identified as a “hyperglycemic factor” contaminating early insulin preparations.15PubMed. Glucagon–Early breakthroughs and recent discoveries But glucagon’s hormonal status wasn’t firmly established until the 1950s, when its chemical structure was worked out and Roger Unger developed the first reliable blood test for it.16PubMed. Glucagon 100 years. Important, but still enigmatic For decades afterward, glucagon was treated as insulin’s lesser sibling, a simple “catabolic hormone” whose only real job was pushing glucose out of the liver. That narrow view is changing. Researchers now recognize that glucagon has effects on amino acid metabolism, lipid handling, and energy expenditure that go well beyond blood sugar, which is why it’s becoming a drug target in its own right.
Dual-Hormone Artificial Pancreas Systems
Most insulin pumps and automated delivery systems used by people with type 1 diabetes control blood sugar with insulin alone. The problem is that insulin can only pull blood sugar down; once it’s injected or infused, there’s no way to recall it if blood sugar starts dropping too fast. Dual-hormone artificial pancreas systems aim to fix this by delivering both insulin and small doses of glucagon, mimicking the two-sided feedback loop the healthy pancreas runs automatically. When the system’s algorithm predicts that blood sugar is about to go too low, it can deliver a micro-dose of glucagon to push it back up, rather than simply stopping insulin and waiting.17PubMed Central. Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions
One of the practical hurdles has been glucagon itself. The hormone is unstable in liquid form and historically needed to be mixed from powder right before use, making it impractical for a pump. Recent advances in peptide engineering and formulation have produced next-generation glucagon analogs that remain stable in solution for much longer, moving dual-hormone pumps closer to everyday clinical use.18ChemBioChem. Engineering Glucagon via Molecular and Formulation Strategies: From Natural Hormone to Effective and Stable Therapeutics Some of the same engineering work is feeding into multi-receptor agonist drugs that activate both the GLP-1 receptor and the glucagon receptor simultaneously, an approach being tested for obesity and metabolic disease. Glucagon, long seen only as something that raises blood sugar, is finding a second life as a therapeutic tool precisely because its metabolic effects extend beyond glucose alone.
When the “Simple Seesaw” Metaphor Falls Short
Most popular descriptions paint the insulin-glucagon relationship as a straightforward back-and-forth: one goes up, the other goes down, blood sugar stays in range. That captures the general direction, but it misses layers of complexity that matter in real physiology. For one, glucagon secretion is controlled by both the alpha cell’s own glucose-sensing machinery and by local signals from neighboring beta and delta cells, and researchers still debate the relative contribution of each under different conditions.19PubMed Central. Glucagon secretion from pancreatic α-cells The two mechanisms aren’t mutually exclusive; they likely operate in parallel, with their relative importance shifting depending on whether glucose is in the low, normal, or high range.
Second, the loop doesn’t operate in isolation. Gut incretins, nervous system input, circulating amino acids, fatty acids, and stress hormones all modulate the insulin-glucagon balance at any given moment. The feedback loop isn’t a thermostat with two wires; it’s more like a thermostat connected to a weather station, a building occupancy sensor, and a calendar that knows what season it is. That complexity is what makes blood sugar regulation remarkably robust in healthy people and remarkably difficult to replicate with technology in those whose systems have broken down.